A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas.

Trial Profile

A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Jul 2016

At a glance

  • Drugs RG 4733 (Primary) ; Vismodegib (Primary)
  • Indications Brain metastases; Gastrointestinal stromal tumours; Liposarcoma; Sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 06 Nov 2014 Planned primary completion date changed from 1 Nov 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
    • 09 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top